Abstract
Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.
Keywords: Cancer Therapy, Evolution of Resistance, Evolutionary Dynamics
Current Pharmaceutical Design
Title: Evolution of Resistance to Cancer Therapy
Volume: 12 Issue: 3
Author(s): Franziska Michor, Martin A. Nowak and Yoh Iwasa
Affiliation:
Keywords: Cancer Therapy, Evolution of Resistance, Evolutionary Dynamics
Abstract: Acquired drug resistance is a major limitation for successful treatment of cancer. Resistance emerges due to drug exclusion, drug metabolism and alteration of the drug target by mutation or overexpression. Depending on therapy, the type of cancer and its stage, one or several genetic or epigenetic alterations are necessary to confer resistance to treatment. The fundamental question is the following: if a genetically diverse population of replicating cancer cells is subjected to chemotherapy that has the potential to eradicate it, what is the probability of emergence of resistance? Here, we review a general mathematical framework based on multi-type branching processes designed to study the dynamics of escape of replicating organisms from selection pressures. We apply the general model to evolution of resistance of cancer cells and discuss examples for diverse mechanisms of resistance. Our theory shows how to estimate the probability of success for any treatment regimen.
Export Options
About this article
Cite this article as:
Michor Franziska, Nowak A. Martin and Iwasa Yoh, Evolution of Resistance to Cancer Therapy, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201956
DOI https://dx.doi.org/10.2174/138161206775201956 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Polyketide Natural Products, Acetogenins from Graviola (Annona muricata L), its Biochemical, Cytotoxic Activity and Various Analyses Through Computational and Bio-Programming Methods
Current Pharmaceutical Design Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) Evaluation of Cytotoxic Mechanisms of Clinacanthus Nutans Extracts in Cancer Cells
The Natural Products Journal The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells
Current Cancer Therapy Reviews RNAi in Plasmodium
Current Pharmaceutical Design Structure and Mechanism of Arylamine N-Acetyltransferases
Current Topics in Medicinal Chemistry Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Pentoxifylline and Local Honey for Radiation-Induced Burn Following Breast Conservative Surgery
Current Clinical Pharmacology Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial [Hot Topic: Applications of Graph Theory, Network Theory, and Chemotopology to Structure-Activity Relationships and Characterization of Metabolic Processes (Guest Editors: Subhash C. Basak and Guillermo Restrepo)]
Current Computer-Aided Drug Design Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo
Current Pharmaceutical Design